CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited has 2 licensing announcements in this dataset, dated 2026-01-30 to 2026-07-02.
- Country / operating region
- China
- Ticker
- 01093.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Pharmaceutical research and development
- Website
- 查無
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| SYH2082 | GLP-1R; GIPR; additional undisclosed targets | peptide | preclinical | 2026-01-30 |
| Two siRNA preclinical candidate programs | 查無 | other | preclinical | 2026-07-02 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| DP303c | PHASE3 | NCT06313086 | RECRUITING | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-05-10 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-01-30 | AstraZeneca | SYH2082 | USD 1200m | 查無 | 查無 | 查無 | Development / regulatory ≤ USD 3500m |
| 2026-07-02 | AstraZeneca | Two siRNA preclinical candidate programs | USD 30m | 查無 | ≤ USD 1740m | 查無 | Development ≤ USD 540m Sales ≤ USD 1200m |
| Counterparty | Territory | Royalties |
|---|---|---|
| AstraZeneca | Worldwide excluding mainland China, Taiwan, Hong Kong and Macau | Tiered royalties. |
| AstraZeneca | Worldwide option rights; CSPC retains China rights to one candidate | Potential single-digit royalties on net sales. |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無